HPDL Knockout HT29 Polyclonal Cells

Product Type:
Polyclonal Cell Population
Species:
Homo sapiens (Human)

Datasheet

HPDL Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited HT29 colorectal adenocarcinoma cell population with targeted disruption of the HPDL gene, encoding a mitochondrial protein linked to tyrosine metabolism. This model enables investigation of HPDL function in cancer cell fitness, mitochondrial dysfunction, and drug resistance. Key pathway connections include the tyrosine catabolic enzymes HPD and FAH, and the product is suitable for western blotting, metabolic flux, and cell viability assays, supporting research into colorectal cancer biology and related neurodevelopmental disorders.

Inquire Now

In stock

Ships next business day

Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice

Disclaimer:

For Research Use Only

Characteristics

Host Cell

HT29

Gene Name

HPDL

Gene Identifier

NCBI Gene ID 84842

Storage

Liquid nitrogen (LN2)
Culture Conditions

Growth medium

McCoy's 5A

Supplement(s)

10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

Temperature

37°C

Atmosphere

5% CO₂
Quality Control

Sterility testing

The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

Mycoplasma testing

Negative for mycoplasma through PCR analysis
Disclaimer

Intended Use

This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer

Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

HPDL Knockout HT29 Polyclonal Cells are a heterogeneous population of HT29 colorectal adenocarcinoma cells engineered through CRISPR/Cas9-mediated gene disruption to eliminate HPDL protein expression.

This polyclonal knockout pool provides a robust loss-of-function model for studying the cellular consequences of HPDL deficiency in a human epithelial cancer background.

The product is supplied as a mixed population, reflecting the biological variability inherent in polyclonal editing and enabling cost-effective, high-throughput screening assays without the need for clonal isolation.

Researchers can immediately leverage this system for functional genomics, drug response profiling, and mitochondrial biology investigations.